← Back to Search

Glucagon-like peptide-1 receptor agonist

Dulaglutide Injection for Stress Hyperglycemia

Phase 4
Waitlist Available
Led By Francisco Pasquel, MD, MPH
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 days postoperatively
Awards & highlights

Study Summary

This trial will study whether dulaglutide can help prevent stress-hyperglycemia and the metabolic inflammatory response during surgery.

Eligible Conditions
  • Stress Hyperglycemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 days postoperatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 7 days postoperatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of Blood Glucose levels (BG) > 140 mg/dl During Post Operative Period
Secondary outcome measures
Amount of SC Insulin
Days of Subcutaneous (SC) Insulin After Discontinuation of CII
Duration of CII
+15 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dulaglutide ArmExperimental Treatment1 Intervention
Participants without a history of DM who are randomized to receive a single injection of dulaglutide (0.75 mg/0.5 mL solution in a single-dose pen) one to three days prior to surgery.
Group II: Placebo ArmPlacebo Group1 Intervention
Participants without a history of DM who are randomized to receive a single injection of a placebo (saline injection of 0.5 mL pre-drawn solution) one to three days prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dulaglutide
FDA approved

Find a Location

Who is running the clinical trial?

National Institute of General Medical Sciences (NIGMS)NIH
268 Previous Clinical Trials
248,729 Total Patients Enrolled
Emory UniversityLead Sponsor
1,636 Previous Clinical Trials
2,560,542 Total Patients Enrolled
Francisco Pasquel, MD, MPHPrincipal Investigator - Emory University
Emory University

Media Library

Dulaglutide Injection (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT03743025 — Phase 4
Stress Hyperglycemia Research Study Groups: Dulaglutide Arm, Placebo Arm
Stress Hyperglycemia Clinical Trial 2023: Dulaglutide Injection Highlights & Side Effects. Trial Name: NCT03743025 — Phase 4
Dulaglutide Injection (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03743025 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the study open to individuals above a certain age?

"This trial is only suitable for individuals aged 40 to 80. For those that are younger or older, there are alternative clinical trials available."

Answered by AI

What medical conditions can be addressed with Dulaglutide Injection?

"Dulaglutide Injection is a popular medication for treating type 2 diabetes mellitus. This injection can also reduce cardiovascular risk, support proper diet and exercise regimens, and more."

Answered by AI

What is the current enrollment size for this clinical trial?

"Affirmative, the details available on clinicaltrials.gov affirms that this trial is actively searching for suitable participants. This investigation commenced on March 8th 2019 and was most recently edited on August 2nd 2022. The study intends to recruit 60 individuals across 3 sites."

Answered by AI

Are there particular types of participants deemed most advantageous for this research?

"This medical study is seeking 60 individuals, aged between 40 to 80 years old and with a BMI of 25mg/kg2 or higher, who are currently suffering from hyperglycemia. An additional requirement for potential participants involves having no prior history of diabetes or hyperglycemia."

Answered by AI

Are there any remaining slots available for participants in this clinical experiment?

"Affirmative. Clinicaltrials.gov records indicate that recruitment for this medical research, which was first posted in March 2019, is ongoing. The study requires the enlistment of 60 people from 3 different sites."

Answered by AI

What potential adverse effects might arise from Dulaglutide Injection?

"The safety of Dulaglutide Injection has been thoroughly established, scoring a 3 on our 1-3 scale due to the completion of Phase 4 clinical trials."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
Francisco Pasquel 2019. "Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03743025.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top